Sichuan Kelun Pharmaceutical Co Ltd.
https://en.kelun.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Sichuan Kelun Pharmaceutical Co Ltd.
ESMO 24: Keytruda Shows Strong OS Benefit In Two Women's Cancers
Merck & Co has presented lots of data on its huge-earning checkpoint inhibitor at the Barcelona congress, the highlights being impressive first-time overall survival results for Keytruda in cervical cancer and early-stage triple-negative breast cancer.
Merck & Co. Drops Kelun Claudin 18.2 ADC But Exercises Bispecific Option
The changes mark the second major revision to the 2022 antibody-drug conjugate-focused alliance between the US and Chinese firms, which is now focusing on ADCs against Trop2, Nectin-4 and other undisclosed targets. Meanwhile, the results from other trials with Claudin 18.2 ADCs have used varying definitions of high expression, with differing results.
Anti-TROP2 ADCs Lung Cancer Futures Likely Lie In Earlier-Stage Disease
The discussant at ASCO’s NSCLC session said the field would need to “manage expectations” as the drugs do not appear to beat chemotherapy in all-comers.
Bladder Cancer Failure Is Another Setback For Gilead’s Trodelvy
A missed survival endpoint in the TROPiCS-04 confirmatory trial could spell end to Trodelvy's bladder cancer use, but Gilead is more hopeful of lung cancer success.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
- Nutraceuticals
- Vaccines
-
Biotechnology
- Gene Therapy, Cell Therapy
-
Large Molecule
- Antibodies
-
Drug Discovery Technologies
-
Molecular Diversity
- Natural Products
-
Molecular Diversity
- Other Names / Subsidiaries
-
- Guangxi Kelun Pharmaceutical Co Ltd
- Hunan Kelun Pharmaceutical Co Ltd
- Hubei Kelun Pharmaceutical Co Ltd
- Kelun Pharmaceutical Group
- KLUS Pharma Inc
- Shandong Kelun Pharmaceutical Co Ltd
- Sichuan Kelun Pharmaceutical Research Co Ltd
- Suzhou Kelun Pharmaceutical Research Co Ltd
- Sichuan Xindi Pharmaceutical Chemicals Co Ltd
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice